Skip to content

Identification of Nerves Using Fluorescein Sodium

Intraoperative Nerve Identification With Fluorescein Sodium

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06054178
Enrollment
8
Registered
2023-09-26
Start date
2024-11-07
Completion date
2025-05-22
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck, Thyroid Disease, Thyroidectomy

Brief summary

The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.

Interventions

Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg

Sponsors

Stanford University
Lead SponsorOTHER
National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Experimental: Fluorescein sodium during surgery Subjects undergoing parotid surgery for benign conditions will have fluorescein sodium administered intravenously after induction, and fluorescence imaging will be performed to visualize nerves intraoperatively

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female subjects 2. 18 years or older 3. Scheduled for open head and neck surgery

Exclusion criteria

1. Inability or unwillingness of a subject 2. Pregnancy 3. Vulnerable or disadvantaged population (pregnant women, decisionally impaired, homeless, employees, students) 4. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study 5. History of adverse reaction to fluorescein including allergy. 6. History of renal failure or chronic kidney disease

Design outcomes

Primary

MeasureTime frameDescription
Facial Nerve Correlation of Fluorescein Sodium With ElectrostimulationIntraoperative (day 1, up to 1 minute to assess)Surgeon assessment of fluorescence correlation with electrostimulation using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation
Correlation of Fluorescein Sodium With Surgeons' Visual Assessment of NerveIntraoperative (day 1, up to 1 minute to assess)Survey of surgeon visual assessment of nerve under white light compared to fluorescence using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation.
Ratio of Nerve Fluorescence Compared to Background TissueIntraoperative (Day 1, Up to 20 minutes to assess)Weber contrast ratio of nerve fluorescence intensity compared to background fluorescence intensity

Secondary

MeasureTime frameDescription
Average Dose of Sodium Fluorescein AdministrationIntraoperative (day 1)Average dose of sodium fluorescein administered in mg/kg
Time to Nerve VisualizationIntraoperative (day 1, up to approximately 200 minutes for initial imaging)Amount of time (in minutes) to nerve fluorescence after sodium fluorescein adminstration

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORTulio Valdez, MD

Stanford University

Baseline characteristics

Characteristic
Age, Continuous49.9 years
STANDARD_DEVIATION 20.3
Race/Ethnicity, Customized
Asian
3 Participants
Race/Ethnicity, Customized
Non-white hispanic
1 Participants
Race/Ethnicity, Customized
White
4 Participants
Region of Enrollment
United States
8 Participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
0 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026